Effect of alirocumab on cataracts in patients with acute coronary syndromes

BACKGROUND: Some data suggest that low levels of low-density lipoprotein cholesterol (LDL-C) are associated with risk of cataracts. Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors reduce LDL-C below levels achieved with statins alone. We determined whether the incidence of cataracts...

Descripción completa

Detalles Bibliográficos
Autores principales: Suc, Gaspard, Schwartz, Gregory G., Goodman, Shaun G., Jukema, J. Wouter, Manvelian, Garen, Poulouin, Yann, Pordy, Robert, Scemama, Michel, Szarek, Michael, Steg, Ph. Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276414/
https://www.ncbi.nlm.nih.gov/pubmed/37328736
http://dx.doi.org/10.1186/s12886-023-03012-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276414/
https://www.ncbi.nlm.nih.gov/pubmed/37328736
http://dx.doi.org/10.1186/s12886-023-03012-1

Ejemplares similares